Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 14 studies | 32% ± 10% | |
lung | 11 studies | 30% ± 11% | |
kidney | 8 studies | 28% ± 6% | |
intestine | 8 studies | 28% ± 14% | |
brain | 7 studies | 25% ± 8% | |
bone marrow | 4 studies | 24% ± 5% | |
eye | 4 studies | 31% ± 10% | |
uterus | 4 studies | 27% ± 15% | |
lymph node | 4 studies | 27% ± 6% | |
breast | 4 studies | 18% ± 2% | |
liver | 4 studies | 34% ± 17% | |
pancreas | 3 studies | 39% ± 6% | |
adrenal gland | 3 studies | 21% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 3712.61 | 180 / 180 | 100% | 47.72 | 430 / 430 |
stomach | 100% | 2959.14 | 359 / 359 | 100% | 40.66 | 286 / 286 |
esophagus | 100% | 3728.52 | 1444 / 1445 | 100% | 40.04 | 183 / 183 |
brain | 100% | 4804.00 | 2640 / 2642 | 100% | 65.38 | 705 / 705 |
breast | 100% | 4503.53 | 459 / 459 | 100% | 54.76 | 1117 / 1118 |
skin | 100% | 6044.35 | 1807 / 1809 | 100% | 103.13 | 472 / 472 |
prostate | 100% | 4096.15 | 245 / 245 | 100% | 59.74 | 501 / 502 |
uterus | 100% | 3903.83 | 170 / 170 | 100% | 48.96 | 458 / 459 |
kidney | 100% | 7802.94 | 89 / 89 | 100% | 91.41 | 898 / 901 |
thymus | 100% | 4496.05 | 653 / 653 | 100% | 69.29 | 602 / 605 |
lung | 100% | 4098.24 | 576 / 578 | 100% | 47.63 | 1153 / 1155 |
bladder | 100% | 4047.81 | 21 / 21 | 99% | 44.41 | 501 / 504 |
intestine | 100% | 3548.35 | 966 / 966 | 99% | 42.22 | 523 / 527 |
pancreas | 100% | 1984.65 | 327 / 328 | 99% | 38.63 | 176 / 178 |
adrenal gland | 100% | 8039.15 | 258 / 258 | 97% | 45.94 | 223 / 230 |
adipose | 100% | 4750.83 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 226.43 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 35.54 | 29 / 29 |
muscle | 100% | 3784.98 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 4438.00 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 39.15 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 36.23 | 1 / 1 |
peripheral blood | 100% | 11783.47 | 928 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3051.66 | 1332 / 1335 | 0% | 0 | 0 / 0 |
heart | 96% | 2326.90 | 828 / 861 | 0% | 0 | 0 / 0 |
liver | 38% | 406.12 | 87 / 226 | 39% | 9.05 | 160 / 406 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032259 | Biological process | methylation |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005739 | Cellular component | mitochondrion |
GO_0106370 | Molecular function | protein-L-histidine N-pros-methyltransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | METTL9 |
Protein name | Protein-L-histidine N-pros-methyltransferase (EC 2.1.1.-) (DORA reverse strand protein) (DREV) (DREV1) (Methyltransferase-like protein 9) (hMETTL9) Methyltransferase like 9 |
Synonyms | CGI-81 DREV |
Description | FUNCTION: Protein-histidine N-methyltransferase that specifically catalyzes 1-methylhistidine (pros-methylhistidine) methylation of target proteins . Mediates methylation of proteins with a His-x-His (HxH) motif (where 'x' is preferably a small amino acid) . Catalyzes methylation of target proteins such as S100A9, NDUFB3, SLC39A5, SLC39A7, ARMC6 and DNAJB12; 1-methylhistidine modification may affect the binding of zinc and other metals to its target proteins . Constitutes the main methyltransferase for the 1-methylhistidine modification in cell . . |
Accessions | H3BQD2 H3BTS9 ENST00000562379.1 ENST00000358154.8 [Q9H1A3-1] H3BRP5 Q9H1A3 ENST00000567404.5 ENST00000569290.1 H3BPE9 ENST00000570074.1 ENST00000562961.1 ENST00000568826.1 H3BM54 H3BN86 ENST00000396014.8 [Q9H1A3-2] |